Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kezar Life Sciences Inc KZR

Healthcare Biotechnology
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical... see more

Recent & Breaking News (NDAQ:KZR)

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire April 8, 2024

Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

Business Wire March 14, 2024

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire March 8, 2024

Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

Business Wire February 28, 2024

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)

PR Newswire December 4, 2023

Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Business Wire November 21, 2023

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Business Wire November 13, 2023

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire November 3, 2023

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire October 9, 2023

Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

Business Wire October 3, 2023

Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

Business Wire September 20, 2023

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

Business Wire August 31, 2023

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Business Wire August 10, 2023

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire August 4, 2023

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire July 7, 2023

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire June 9, 2023

Kezar Life Sciences to Participate in the Jefferies Healthcare Conference

Business Wire May 31, 2023

Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

Business Wire May 11, 2023

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire April 5, 2023

Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Business Wire March 14, 2023